CGTX - COGNITION THERAPEUTICS INC
IEX Last Trade
0.8245
0 0%
Share volume: 49,330
Last Updated: Fri 27 Dec 2024 08:02:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$0.82
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
24.98%
1 Month
92.86%
3 Months
82.37%
6 Months
-54.05%
1 Year
-59.40%
2 Year
-63.46%
Key data
Stock price
$0.82
DAY RANGE
$0.74 - $0.88
52 WEEK RANGE
$0.39 - $2.92
52 WEEK CHANGE
-$58.52
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Lisa R. Ricciardi
Region: US
Website: cogrx.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cogrx.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Cognition Therapeutics, Inc. engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease.
Recent news